- cafead   Apr 25, 2022 at 10:52: PM
via Gossamer bio will end the extension of a phase 2 study for a small molecule ulcerative colitis med that was found to be ineffective—the second time in 18 months the company has seen a top program fail a midstage trial.
article source
article source